Page 17 - 2022-24-中国全科医学

·2958· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

G，et al. Statin use and exacerbations in individuals with chronic of GALATHEA and TERRANOVA studies［J］. Lancet Respir
obstructive pulmonary disease［J］. Thorax，2015，70（1）： Med，2020，8（2）：158-170. DOI：10.1016/S2213-2600（19）
33-40. DOI：10.1136/thoraxjnl-2014-205795. 30338-8.
［80］AHMAD S，ARORA S，KHAN S，et al. Vitamin D and its ［92］CRINER G J，CELLI B R，BRIGHTLING C E，et al.
therapeutic relevance in pulmonary diseases［J］. J Nutr Biochem， Benralizumab for the prevention of COPD exacerbations［J］.
2021，90：108571. DOI：10.1016/j.jnutbio.2020.108571. N Engl J Med，2019，381（11）：1023-1034. DOI：
［81］FU L，FEI J，TAN Z X，et al. Low vitamin D status is associated 10.1056/NEJMoa1905248.
with inflammation in patients with chronic obstructive pulmonary ［93］PAVORD I D，CHANEZ P，CRINER G J，et al. Mepolizumab
disease［J］. J Immunol，2021，206（3）：515-523. DOI： for eosinophilic chronic obstructive pulmonary disease［J］.
10.4049/jimmunol.2000964. N Engl J Med，2017，377（17）：1613-1629. DOI：
［82］ALAVI FOUMANI A，MEHRDAD M，JAFARINEZHAD A， 10.1056/NEJMoa1708208.
et al. Impact of vitamin D on spirometry findings and quality of ［94］RABEK F，CELLIB R，WECHSLERM E，et al. Safety and
life in patients with chronic obstructive pulmonary disease： efficacy of itepekimab in patients with moderate-to-severe COPD：
a randomized，double-blinded，placebo-controlled clinical a genetic association study and randomised，double-blind，phase
trial［J］. Int J Chro Obstruct Pulmon Dis，2019，14：1495- 2a trial［J］. Lancet Respir Med，2021，9（11）：1288-1298.
1501. DOI：10.2147/COPD.S207400. DOI：10.1016/S2213-2600（21）00167-3.
［83］MAHLER D A，HUANG S，TABRIZI M，et al. Efficacy ［95］DAHL R，TITLESTAD I，LINDQVIST A，et al. Effects of an
and safety of a monoclonal antibody recognizing interleukin-8 oral MMP-9 and -12 inhibitor，AZD1236，on biomarkers in
in COPD［J］. Chest，2004，126（3）：926-934. DOI： moderate/severe COPD：a randomised controlled trial［J］. Pulm
10.1378/chest.126.3.926. Pharmacol Ther，2012，25（2）：169-177. DOI：10.1016/j.
［84］RENNARD S I，DALE D C，DONOHUE J F，et al. CXCR2 pupt.2011.12.011.
antagonist MK-7123. A phase 2 proof-of-concept trial for chronic ［96］LUISETTI M，STURANI C，SELLA D，et al. MR889，a
obstructive pulmonary disease［J］. Am J Respir Crit Care Med， neutrophil elastase inhibitor，in patients with chronic obstructive
2015，191（9）：1001-1011. DOI：10.1164/rccm.201405- pulmonary disease：a double-blind，randomized，placebo-
0992OC. controlled clinical trial［J］. Eur Respir J，1996，9（7）：1482-
［85］AARON S D，VANDEMHEEN K L，MALTAIS F，et al. TNFα 1486. DOI：10.1183/09031936.96.09071482.
antagonists for acute exacerbations of COPD：a randomised double- ［97］MA J，ZHENG J，ZHONG N，et al. Effects of YuPingFeng
blind controlled trial［J］. Thorax，2013，68（2）：142-148. granules on acute exacerbations of COPD：a randomized，placebo-
DOI：10.1136/thoraxjnl-2012-202432. controlled study［J］. Int J Chron Obstruct Pulmon Dis，2018，
［86］RENNARD S I，FOGARTY C，KELSEN S，et al. The safety 13：3107-3114. DOI：10.2147/COPD.S170555.
and efficacy of infliximab in moderate to severe chronic obstructive ［98］POLKEY M I，QIU Z H，ZHOU L，et al. Tai Chi and pulmonary
pulmonary disease［J］. Am J Respir Crit Care Med，2007， rehabilitation compared for treatment-naive patients with COPD：a
175（9）：926-934. DOI：10.1164/rccm.200607-995OC. randomized controlled trial［J］. Chest，2018，153（5）：1116-
［87］VAN DER VAART H，KOËTER G H，POSTMA D S，et al. First 1124. DOI：10.1016/j.chest.2018.01.053.
study of infliximab treatment in patients with chronic obstructive ［99］苏琳，李娜 . 慢性阻塞性肺疾病患者气道重塑及 T 淋巴细胞亚
pulmonary disease［J］. Am J Respir Crit Care Med，2005， 群与肺功能的相关分析［J］. 中华医院感染学杂志，2013，23
172（4）：465-469. DOI：10.1164/rccm.200501-147OC. （1）：11-12.
［88］CALVERLEY P M A，SETHI S，DAWSON M，et al. SU L，LI N. Correlation between airway remodeling，T lymphocytes
A randomised，placebo-controlled trial of anti-interleukin-1 subsets and lung function of patients with chronic obstructive
receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease［J］. Chinese Journal of Nosocomiology，
pulmonary disease［J］. Respir Res，2017，18（1）：153. 2013，23（1）：11-12.
DOI：10.1186/s12931-017-0633-7. ［100］时良玺，杨润华 . 中西药免疫调节剂联合应用治疗慢性阻塞
［89］EICH A，URBAN V，JUTEL M，et al. A randomized，placebo- 性肺疾病急性加重期疗效观察［J］. 河北中医，2015，37（7）：
controlled phase 2 trial of CNTO 6785 in chronic obstructive 1015-1017. DOI：10.3969/j.issn.1002-2619.2015.07.020.
pulmonary disease［J］. COPD，2017，14（5）：476-483. SHI L X，YANG R H. Observation of union application of Chinese
DOI：10.1080/15412555.2017.1335697. and Western immunomodulator on acute exacerbation of chronic
［90］BRIGHTLING C E，BLEECKER E R，PANETTIERI R A，et al. obstructive pulmonary disease［J］. Hebei Journal of Traditional
Benralizumab for chronic obstructive pulmonary disease and sputum Chinese Medicine，2015，37（7）：1015-1017. DOI：
eosinophilia：a randomised，double-blind，placebo-controlled， 10.3969/j.issn.1002-2619.2015.07.020.
phase 2a study［J］. Lancet Respir Med，2014，2（11）：891- ［101］GAO Z，JING J，LIU Y. Xiaoqinglong decoction（a traditional
901. DOI：10.1016/S2213-2600（14）70187-0. Chinese medicine）combined conventional treatment for acute
［91］CRINER G J，CELLI B R，SINGH D，et al. Predicting response exacerbation of chronic obstructive pulmonary disease：a systematic
to benralizumab in chronic obstructive pulmonary disease：analyses review and meta-analysis［J］. Medicine（Baltimore），2020，